Lung Cancer

Our Lung Cancer Genomics Community of Practice (CoP) is one of several CoPs we are currently supporting. See below for further details, including future meetings and how to join.

Lead Clinician

Jason Adhikaree, Clinical Associate Professor in Oncology, University of Nottingham

Who is this CoP for?

Adult Oncology
Respiratory Medicine
Thoracic Surgery
Specialist Nurses
Palliative Care

About this Community of Practice

The molecular aberrations in lung cancer is required for all new diagnosis of lung cancer where there are 6 first line licenced treatments. Furthermore, the absence of an EGFR/ALK driver is also required in order to access first line immunotherapy drugs.

Hence timely turnaround and understanding of molecular mutations is vital for treating all patients with systemic therapy.

This also includes adjuvant treatments post-surgery and neo-adjuvant patients requiring chemo-immunotherapy peri- operatively. As a Consultant Medical Oncologist whom interprets NGS via ctDNA pilot studies and routine tissue testing, I am well versed in results interpretation and need. I also appreciate the need to address geographical challenges and divergence so that patients meet the National Optimum lung cancer pathway treatment targets.

Meeting schedule

Information on the recurrent day of the month and time of this CoP will be added shortly.

Details of the first meeting will be added here shortly.

Non-urgent advice: Join this Community of Practice

To join this - or any of our Genomic Communities of Practice - please register (or update) your details via our form here.

Please ensure to select the Community of Practice that you wish to join.

Resources from previous meetings

You will soon be able to access slides and recordings of all Lung Cancer CoP meetings on our FutureNHS workspace.

If you haven't already, you can request access to this platform by following this link (opens in a new tab).